FDA Submission Status Update for ABANTA (Apixaban) by AZURITY
The FDA has received a submission for ABANTA (Apixaban) under NDA221024 from AZURITY, currently under standard review.
Company
Bristol Myers Squibb
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's review of ABANTA (Apixaban) by AZURITY represents a significant development in the anticoagulant market, potentially intensifying competition against established products like Eliquis. Portfolio teams must evaluate how this submission could influence market dynamics and pricing strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any upcoming announcements regarding approval status.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.